文献速递细菌感染、耐药与抗菌药物

头孢他啶-阿维巴坦联合磷霉素治疗多重耐药铜绿假单胞菌

Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa.
PubMed 文献 · J Infect Dis · 2019-01-01

本研究评估头孢他啶-阿维巴坦联合磷霉素对多重耐药铜绿假单胞菌临床分离株CL232的协同作用。棋盘法显示两药协同,全基因组测序和转录组分析揭示β-内酰胺耐药相关基因突变及blaPDC、mexAB-oprM外排泵和murA表达上调。小鼠高菌量感染模型中,联合治疗较单药显著降低菌落形成单位,且耐药突变频率更低。

要点

  • 头孢他啶-阿维巴坦与磷霉素对MDR铜绿假单胞菌CL232显示协同作用。
  • 联合治疗在高菌量小鼠感染模型中较单药显著降低细菌负荷。
  • 联合用药可降低磷霉素单药治疗时耐药突变频率。

核心结论

  • 头孢他啶-阿维巴坦联合磷霉素对缺乏金属β-内酰胺酶的多重耐药铜绿假单胞菌具有治疗潜力。

研究设计与样本

  • 针对MDR铜绿假单胞菌临床分离株CL232,采用棋盘法药敏分析、全基因组测序和转录组分析,并在小鼠高菌量感染模型中评估联合疗效。

主要发现

  • 棋盘法显示头孢他啶-阿维巴坦与磷霉素之间存在协同作用。
  • 菌株携带已知β-内酰胺耐药相关基因突变,且blaPDC、mexAB-oprM外排泵和murA表达上调。
  • 磷霉素单药治疗时耐药突变频率高,与头孢他啶-阿维巴坦联用后耐药突变频率降低。
  • 小鼠感染模型中,联合治疗较静止对照降低约2 log CFU,较溶剂对照降低约5 log CFU。
  • 头孢他啶-阿维巴坦和磷霉素单药分别较静止对照增加约3 log和1 log CFU,仅较溶剂对照降低约1 log和2 log CFU。

临床怎么用

  • 对于缺乏金属β-内酰胺酶的高菌量MDR铜绿假单胞菌感染,可考虑头孢他啶-阿维巴坦联合磷霉素方案。

局限性

  • 研究仅基于单一临床分离株CL232和小鼠模型,结论需进一步临床验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Previously, by targeting penicillin-binding protein 3, Pseudomonas-derived cephalosporinase (PDC), and MurA with ceftazidime-avibactam-fosfomycin, antimicrobial susceptibility was restored among multidrug-resistant (MDR) Pseudomonas aeruginosa. Herein, ceftazidime-avibactam-fosfomycin combination therapy against MDR P. aeruginosa clinical isolate CL232 was further evaluated. Checkerboard susceptibility analysis revealed synergy between ceftazidime-avibactam and fosfomycin. Accordingly, the resistance elements present and expressed in P. aeruginosa were analyzed using whole-genome sequencing and transcriptome profiling. Mutations in genes that are known to contribute to β-lactam resistance were identified. Moreover, expression of blaPDC, the mexAB-oprM efflux pump, and murA were upregulated. When fosfomycin was administered alone, the frequency of mutations conferring resistance was high; however, coadministration of fosfomycin with ceftazidime-avibactam yielded a lower frequency of resistance mutations. In a murine infection model using a high bacterial burden, ceftazidime-avibactam-fosfomycin significantly reduced the P. aeruginosa colony-forming units (CFUs), by approximately 2 and 5 logs, compared with stasis and in the vehicle-treated control, respectively. Administration of ceftazidime-avibactam and fosfomycin separately significantly increased CFUs, by approximately 3 logs and 1 log, respectively, compared with the number at stasis, and only reduced CFUs by approximately 1 log and 2 logs, respectively, compared with the number in the vehicle-treated control. Thus, the combination of ceftazidime-avibactam-fosfomycin was superior to either drug alone. By employing a "mechanism-based approach" to combination chemotherapy, we show that ceftazidime-avibactam-fosfomycin has the potential to offer infected patients with high bacterial burdens a therapeutic hope against infection with MDR P. aeruginosa that lack metallo-β-lactamases.

来源:J Infect Dis,查看原文。版权归原作者所有。

引用

  1. Papp-Wallace KM, Zeiser ET, Becka SA, et al. Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa. J Infect Dis. 2019. PMID: 31099835. doi:10.1093/infdis/jiz149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。